224 results on '"Gidaro, T"'
Search Results
52. Baseline data from a European prospective and longitudinal natural history study of patients with type 2 and 3 spinal muscular atrophy – NatHis-SMA
53. ClinBio-GNE: A longitudinal clinical, functional and imaging evaluation of patients affected by GNE myopathy
54. Assessment of grip strength in Duchenne muscular dystrophy
55. New criteria for assessing the achievement of upper limbs in FSHD patients
56. Assessment of lower limbs in FSHD: The ActiMyo as a new outcome for home-monitoring
57. Feasibility of magneto-inertial motion analysis in non-ambulant patients with spinal muscular atrophy
58. X-linked myotubular myopathy in ambulant patients
59. Baseline data from patients with myotubular myopathy enrolled in a European prospective and longitudinal natural history study
60. Upper and lower extremity muscle strength decline over 1 year in a prospective, observational GNE-myopathy natural history study
61. Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy
62. Non-ambulant duchenne patients theoretically treatable by exon 53 skipping have severe phenotype
63. Longitudinal study for GNE gene (ClinBio-GNE)
64. Natural history and functional status of patients with myotubular myopathy enrolled in a prospective and longitudinal study
65. P.341 - Results of a Phase 1b/2 Study of ATYR1940 in adolescents and young adults with early onset facioscapulohumeral muscular dystrophy (FSHD) (ATYR1940-C-003)
66. P.247 - New myotubular myopathy classification
67. P.250 - Longitudinal data of patients with myotubular myopathy enrolled in a European prospective and longitudinal natural history study
68. P.176 - GNE-myopathy (HIBM): Upper and lower extremity muscle strength declines over time in a prospective study
69. P.124 - Longitudinal data of the European prospective natural history study of patients with type 2 and 3 spinal muscular atrophy
70. Predictive role of NCAM in the identification of patients with HIBM due to GNE mutations with atypical clinical phenotype
71. alpha-Dystroglycan does not play a major pathogenic role in autosomal recessive hereditary inclusion-body myopathy
72. G.P.80
73. T.P.13
74. G.O.5
75. G.P.39
76. G.P.133
77. Atrophy, Fibrosis, and Increased PAX7-Positive Cells in Pharyngeal Muscles of Oculopharyngeal Muscular Dystrophy Patients
78. P.331 - Assessment of grip strength in Duchenne muscular dystrophy
79. P.268 - Assessment of lower limbs in FSHD: The ActiMyo as a new outcome for home-monitoring
80. P.267 - New criteria for assessing the achievement of upper limbs in FSHD patients
81. P.273 - Upper and lower extremity muscle strength decline over 1 year in a prospective, observational GNE-myopathy natural history study
82. P.272 - ClinBio-GNE: A longitudinal clinical, functional and imaging evaluation of patients affected by GNE myopathy
83. P.184 - Simultaneous MFN2 and GDAP1 gene mutation cause severe Charcot–Marie–Tooth type 2 phenotype
84. P.91 - X-linked myotubular myopathy in ambulant patients
85. P.92 - Baseline data from patients with myotubular myopathy enrolled in a European prospective and longitudinal natural history study
86. P.44 - Baseline data from a European prospective and longitudinal natural history study of patients with type 2 and 3 spinal muscular atrophy – NatHis-SMA
87. P.43 - Feasibility of magneto-inertial motion analysis in non-ambulant patients with spinal muscular atrophy
88. P.16.12 OPMD from the myoblast’s and fibroblast’s point of view
89. G.P.106 Immunohistochemical study of cricopharyngeal muscle in oculopharyngeal muscular dystrophy
90. P2.64 Muscle imaging in hereditary inclusion-body myopathy
91. P2.45 Proteomic studies of muscle progenitor cells in affected and non-affected oculopharyngeal muscular dystrophy muscles
92. G.P.318 - Longitudinal study for GNE gene (ClinBio-GNE)
93. G.P.296 - Natural history and functional status of patients with myotubular myopathy enrolled in a prospective and longitudinal study
94. Analysis of NCAM helps identify unusual phenotypes of hereditary inclusion-body myopathy
95. G.P.5.05 Transient overexpression of the Rho family exchange factor GEFT stimulates myogenic differentiation of inclusion-body myositis (IBM) mesoangioblasts
96. G.P.17.05 Predictive role of NCAM in the identification of patients with HIBM due to GNE mutations with atypical clinical phenotype
97. G.P.13.13 Age-related abnormalities and reduced expression of the Notch ligand Delta in IBM primary muscle cultures. A clue for diminished regenerative potential of satellite cells in IBM muscle?
98. G.P.13.14 Ex vivo treatment with TSA and IGF-1 induces myogenic differentiation of inclusion-body myositis mesoangioblasts
99. NCAM is hyposialylated in hereditary inclusion body myopathy due to GNE mutations
100. T.P.13: Upper limb performance changes during a one-year follow-up in non-ambulant patients with Duchenne muscular dystrophy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.